The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Co-Administered With Atorvastatin, in Subjects with Hypertriglyceridemia 4 g/day 16 weeks NCT00435045 Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid-Ethyl Esters) in Recurrent ...

It is generally well appreciated that the pharmaceutical industry has entered a period of revenue underperformance. However, the severity of this underperformance, even when measured against ...

In turn, insurers are forcing generic substitution of blockbusters such as Lipitor, Crestor and Plavix ... Pfizer, Roche, Sanofi Aventis and Sanofi Pasteur. He has been closely involved in the ...

Ranbaxy reportedly reaped $500 million in sales from its knockoff of Pfizer's cholesterol pill Lipitor during its first ... and innovation for the future. Sanofi has taken a small step towards ...

The most commonly used statins were as follows: simvastatin (4593), atorvastatin (4510), rosuvastatin (733 ... We express our gratitude to SANOFI and ROVI for supporting this Registry with an ...

The upadacitinib study gave similar results, showing that the JAKi had no clinically relevant effect on rosuvastatin and atorvastatin pharmacokinetics ... Pfizer, Roche, Sanofi, Samsung Bioepis, ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi ...